加拿大吸毒人群中HIV传播性耐药模式及一线抗病毒治疗病毒学应答
该研究基于加拿大温哥华两个前瞻性吸毒人群队列,分析573例未治疗HIV感染者的传播性耐药(TDR)模式及其对一线抗病毒治疗病毒学结局的影响。TDR者治疗第一年病毒学失败风险更高。
要点
- 吸毒人群TDR总患病率9.8%,2010-2015年升至21.1%,以NNRTI耐药为主。
核心结论
- 1996至2015年温哥华吸毒人群中TDR患病率显著上升。
- TDR者一线ART病毒学失败风险更高,可能与不恰当ART处方及慢性感染者未检测到的少数耐药变异有关。
- 支持在该人群HIV感染早期进行基线耐药检测以指导ART选择。
研究设计与样本
- 数据来自加拿大温哥华两个前瞻性吸毒人群队列。
- 纳入573例未接受ART的HIV感染者,其中18%为近期感染。
- 分析1996-2015年TDR模式及其对一线ART病毒学结局的影响。
主要发现
- 总体TDR患病率为9.8%(95%CI 7.3%-12.2%)。
- NNRTI相关耐药突变最常见(5.4%),其次为核苷类逆转录酶抑制剂(3.0%)和蛋白酶抑制剂(1.9%)。
临床怎么用
- 在该吸毒人群设置中,HIV感染早期应进行基线耐药检测以指导一线ART选择。
- 对吸毒人群处方一线ART时需关注TDR尤其是NNRTI耐药对病毒学应答的影响。
局限性
- TDR者病毒学失败风险较高可能部分归因于不恰当ART处方及慢性感染者未检测到的少数耐药变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transmitted drug resistance (TDR) may compromise response to antiretroviral therapy (ART). However, there are limited data on TDR patterns and impacts among people who use illicit drugs (PWUD). METHODS: Data were drawn from 2 prospective cohorts of PWUD in Vancouver, Canada. We characterized patterns of TDR among human immunodeficiency virus (HIV)-infected PWUD, and assessed its impacts on first-line ART virological outcomes. RESULTS: Between 1996 and 2015, among 573 ART-naive PWUD (18% with recent HIV infection), the overall TDR prevalence was 9.8% (95% confidence interval [CI], 7.3%-12.2%), with an increasing trend over time, from 8.5% in 1996-1999 to 21.1% in 2010-2015 (P = .003), mainly driven by resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs). TDR-associated mutations were more common for NNRTIs (5.4%), followed by nucleoside reverse transcriptase inhibitors (3.0%) and protease inhibitors (1.9%). TDR prevalence was lower among recently infected PWUD (adjusted odds ratio, 0.39 [95% CI, .15-.87]). Participants with TDR had higher risk of virological failure than those without TDR (log-rank P = .037) in the first year of ART. CONCLUSIONS: Between 1996 and 2015, TDR prevalence increased significantly among PWUD in Vancouver. Higher risk of virological failure among PWUD with TDR may be explained by some inappropriate ART prescribing, as well as undetected minority resistant variants in participants with chronic HIV infection. Our findings support baseline resistance testing early in the course of HIV infection to guide ART selection among PWUD in our setting.
引用
- Socías ME, Nosova E, Kerr T, et al. Patterns of Transmitted Drug Resistance and Virological Response to First-line Antiretroviral Treatment Among Human Immunodeficiency Virus-Infected People Who Use Illicit Drugs in a Canadian Setting. Clin Infect Dis. 2017. PMID: 28482025. doi:10.1093/cid/cix428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。